Three Key Considerations For Optimizing Process Development
Source: Cytiva
By Amber Hoskins
Prioritizing the optimization of process development (PD) before scaling up or out is crucial to prevent your inefficiencies from scaling with you. In a recent webinar, Gary M. Pigeau, Ph.D., Director of Research and Development, Nucleic Acid Therapeutics at Cytiva discussed three key considerations for optimizing PD: timing, technology, and people. Gain insight into the importance of evaluating PD timelines, technology and process transfer to GMP manufacturing, and choosing the right PD partners.
access the Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.
Subscribe to Biosimilar Development
X
Subscribe to Biosimilar Development
Cytiva
This website uses cookies to ensure you get the best experience on our website. Learn more